Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Federal Trade Commission
Fish and Richardson
QuintilesIMS
Daiichi Sankyo
Express Scripts
Healthtrust
Moodys
Baxter
Cipla

Generated: October 21, 2017

DrugPatentWatch Database Preview

Amarin Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for AMARIN PHARMS, and what generic alternatives to AMARIN PHARMS drugs are available?

AMARIN PHARMS has two approved drugs.

There are twenty-five US patents protecting AMARIN PHARMS drugs and there have been two Paragraph IV challenges on AMARIN PHARMS drugs in the past three years.

There are one hundred and seven patent family members on AMARIN PHARMS drugs in forty countries and two supplementary protection certificates in one country.

Summary for Applicant: Amarin Pharms

International Patents:107
US Patents:25
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for AMARIN PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
icosapent ethyl
Capsules500 mg
VASCEPA
8/29/2017
icosapent ethyl 
Capsules1 g
VASCEPA
7/26/2016
icosapent ethyl
Capsules1 g
VASCEPA
1/15/2013

Non-Orange Book Patents for Amarin Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,056,088Pharmaceutical compositions comprising fatty acids► Subscribe
9,138,415Stable pharmaceutical composition and methods of using same► Subscribe
9,060,983Stable pharmaceutical composition and methods of using same► Subscribe
8,691,871Methods of treating mixed dyslipidemia► Subscribe
6,384,077 Highly purified EPA for treatment of schizophrenia and related disorders► Subscribe
8,642,077Stable pharmaceutical composition and methods of using same► Subscribe
9,072,715Stable pharmaceutical composition and methods of using same► Subscribe
8,663,662Stable pharmaceutical composition and methods of using same► Subscribe
8,680,144Methods of treating mixed dyslipidemia► Subscribe
8,618,166Methods of treating mixed dyslipidemia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Amarin Pharms Drugs

Country Document Number Estimated Expiration
Singapore10201605794P► Subscribe
New Zealand627238► Subscribe
Brazil0007743► Subscribe
Russian Federation2011148362► Subscribe
World Intellectual Property Organization (WIPO)0044361► Subscribe
Australia3065700► Subscribe
Singapore10201610916S► Subscribe
CroatiaP20130811► Subscribe
Israel144502► Subscribe
European Patent Office1417963► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Amarin Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0009Belgium► SubscribePRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION:
C0037Belgium► SubscribePRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Queensland Health
QuintilesIMS
Covington
McKesson
Chinese Patent Office
Colorcon
Moodys
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot